{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:45:36Z","timestamp":1784245536399,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204870\/Z\/16\/Z"],"award-info":[{"award-number":["204870\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT\/204870\/Z\/16\/Z"],"award-info":[{"award-number":["WT\/204870\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["A1601"],"award-info":[{"award-number":["A1601"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI051355"],"award-info":[{"award-number":["R01AI051355"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ebiom.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T01:43:05Z","timestamp":1573782185000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation"],"prefix":"10.1016","volume":"50","author":[{"given":"Ilona","family":"Baraniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-4088","authenticated-orcid":false,"given":"Ariane C.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Langstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Piras-Douce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ebiom.2019.11.005_bib0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.005_bib0002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"},{"issue":"24","key":"10.1016\/j.ebiom.2019.11.005_bib0003","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1001\/jama.1989.03420240121038","article-title":"The indirect effects of cytomegalovirus infection on the outcome of organ transplantation","volume":"261","author":"Rubin","year":"1989","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ebiom.2019.11.005_bib0004","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1086\/379077","article-title":"Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome","volume":"37","author":"Kempen","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.005_bib0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.spid.2004.09.011","article-title":"Congenital cytomegalovirus infection: outcome and diagnosis","volume":"16","author":"Ross","year":"2005","journal-title":"Semin Pediatr Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2019.11.005_bib0006","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1753495X14552719","article-title":"Congenital cytomegalovirus infection: clinical presentation, epidemiology, diagnosis and prevention","volume":"7","author":"van Zuylen","year":"2014","journal-title":"Obstet Med"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.005_bib0007","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \"silent\" global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.005_bib0008","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/rmv.664","article-title":"CMV in critically ill patients: pathogen or bystander?","volume":"20","author":"Limaye","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ebiom.2019.11.005_bib0009","series-title":"Vaccines for the 21st century: a tool for decisionmaking","article-title":"The national academies collection: reports funded by national institutes of health","year":"2000"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005355","article-title":"The march towards a vaccine for congenital CMV: rationale and models","volume":"12","author":"Bialas","year":"2016","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.ebiom.2019.11.005_bib0011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2055-6640(20)30872-4","article-title":"Cytomegalovirus vaccines under clinical development","volume":"2","author":"Schleiss","year":"2016","journal-title":"J Virus Erad"},{"issue":"12","key":"10.1016\/j.ebiom.2019.11.005_bib0012","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.ebiom.2019.11.005_bib0013","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.ebiom.2019.11.005_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"issue":"9773","key":"10.1016\/j.ebiom.2019.11.005_bib0015","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ebiom.2019.11.005_bib0016","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"10.1016\/j.ebiom.2019.11.005_bib0017","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein b subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.005_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/425905","article-title":"Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir","volume":"191","author":"Mattes","year":"2005","journal-title":"J Infect Dis"},{"issue":"Pt 2","key":"10.1016\/j.ebiom.2019.11.005_bib0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1099\/0022-1317-76-2-309","article-title":"Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease","volume":"76","author":"Fox","year":"1995","journal-title":"J Gen Virol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.005_bib0020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/CVI.00422-09","article-title":"Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein b antibody in serum","volume":"17","author":"Hackett","year":"2010","journal-title":"Clin Vac Immunol CVI"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.005_bib0021","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/jvi.67.2.703-710.1993","article-title":"Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58\/116 (gB), as determined with human monoclonal antibodies","volume":"67","author":"Ohlin","year":"1993","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.005_bib0022","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1073\/pnas.1114966108","article-title":"Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells","volume":"109","author":"Reeves","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.005_bib0023","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow's vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.005_bib0024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/clinids\/5.2.205","article-title":"Latent infection and the elusive cytomegalovirus","volume":"5","author":"Jordan","year":"1983","journal-title":"Rev Infect Dis"},{"issue":"18","key":"10.1016\/j.ebiom.2019.11.005_bib0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJM200105033441804","article-title":"Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity","volume":"344","author":"Boppana","year":"2001","journal-title":"N Engl J Med"},{"issue":"Pt 4","key":"10.1016\/j.ebiom.2019.11.005_bib0026","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/vir.0.83523-0","article-title":"Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection","volume":"89","author":"Gerna","year":"2008","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1958","article-title":"Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient","volume":"28","author":"Baraniak","year":"2018","journal-title":"Rev Med Virol"},{"issue":"4","key":"10.1016\/j.ebiom.2019.11.005_bib0028","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2019.11.005_bib0029","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-017-0038-0","article-title":"Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein b (gB) and immune sera induced by gB\/MF59 vaccination","volume":"2","author":"Li","year":"2017","journal-title":"NPJ Vaccines"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419307467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419307467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:57:29Z","timestamp":1762455449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419307467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":29,"alternative-id":["S2352396419307467"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.005","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}